Rep. Thomas H. Kean, Jr. Sells Off Shares of Johnson & Johnson (NYSE:JNJ)

Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently sold shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on September 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Johnson & Johnson stock on August 27th. The trade occurred in the Representative’s “STATE STREET BANK & TRUST CO.” account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 8/27/2026.
• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 8/27/2026.
• Purchased $1,001 – $15,000 in shares of MasTec (NYSE:MTZ) on 8/21/2026.
• Sold $1,001 – $15,000 in shares of Stryker (NYSE:SYK) on 7/22/2026.
• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 7/22/2026.
• Purchased $1,001 – $15,000 in shares of Toast (NYSE:TOST) on 7/8/2026.
• Purchased $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 7/8/2026.
• Purchased $1,001 – $15,000 in shares of ESAB (NYSE:ESAB) on 7/7/2026.
• Purchased $1,001 – $15,000 in shares of EQT (NYSE:EQT) on 7/7/2026.
• Sold $1,001 – $15,000 in shares of Analog Devices (NASDAQ:ADI) on 6/30/2026.

Johnson & Johnson Price Performance

JNJ stock traded down $3.00 on Tuesday, hitting $263.32. 1,028,009 shares of the company’s stock traded hands, compared to its average volume of 8,030,831. The stock has a market cap of $634.57 billion, a price-to-earnings ratio of 30.58, a P/E/G ratio of 2.54 and a beta of 0.24. Johnson & Johnson has a 1-year low of $173.33 and a 1-year high of $281.07. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The stock has a fifty day moving average of $263.18 and a 200-day moving average of $246.08.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. During the same quarter in the previous year, the business posted $2.77 earnings per share. The firm’s quarterly revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, analysts forecast that Johnson & Johnson will post 11.61 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were issued a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date was Tuesday, August 25th. Johnson & Johnson’s payout ratio is presently 62.11%.

Institutional Investors Weigh In On Johnson & Johnson

Several hedge funds have recently bought and sold shares of JNJ. Silver Coast Investments LLC lifted its position in Johnson & Johnson by 3.8% during the second quarter. Silver Coast Investments LLC now owns 1,066 shares of the company’s stock worth $271,000 after buying an additional 39 shares in the last quarter. Townsend Asset Management Corp NC ADV raised its holdings in Johnson & Johnson by 0.6% during the second quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company’s stock worth $1,630,000 after purchasing an additional 39 shares in the last quarter. Triumph Capital Management lifted its position in shares of Johnson & Johnson by 1.6% during the 2nd quarter. Triumph Capital Management now owns 2,531 shares of the company’s stock worth $643,000 after buying an additional 39 shares during the last quarter. Denali Advisors LLC grew its position in shares of Johnson & Johnson by 1.2% in the 2nd quarter. Denali Advisors LLC now owns 3,305 shares of the company’s stock valued at $839,000 after buying an additional 40 shares during the last quarter. Finally, Beaird Harris Wealth Management LLC raised its stake in Johnson & Johnson by 1.8% during the 4th quarter. Beaird Harris Wealth Management LLC now owns 2,422 shares of the company’s stock worth $501,000 after acquiring an additional 42 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 23,054 shares of the firm’s stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the transaction, the executive vice president owned 23,003 shares of the company’s stock, valued at approximately $5,779,963.81. This trade represents a 50.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 87,569 shares of company stock worth $23,064,544. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Stifel Nicolaus set a $260.00 target price on Johnson & Johnson in a research report on Wednesday, July 15th. Argus set a $300.00 price objective on Johnson & Johnson in a report on Wednesday, July 29th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $282.00 price objective on shares of Johnson & Johnson in a research note on Thursday, July 16th. Wall Street Zen cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Finally, Johnson Rice restated a “buy” rating on shares of Johnson & Johnson in a report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $274.13.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Strong RYBREVANT cancer data: J&J reported that RYBREVANT plus chemotherapy produced median overall survival of 34.3 months in patients with EGFR exon 20 insertion-positive non-small cell lung cancer—the longest reported result for this population. The data support the drug’s commercial growth potential and broader oncology strategy. RYBREVANT survival results
• Positive Sentiment: Improved treatment experience for RYBREVANT FASPRO: Phase 2b COPERNICUS results showed low rates of rash, blood clots and administration-related reactions when subcutaneous RYBREVANT FASPRO was combined with LAZCLUZE and preventive strategies. Fewer than 1% of patients discontinued treatment because of treatment-related events after one year, potentially supporting adoption. RYBREVANT FASPRO COPERNICUS results
• Positive Sentiment: Analyst Buy rating and possible DePuy Synthes sale: TD Cowen maintained a Buy rating with a $300 price target, citing oncology momentum and the possibility of selling or separating the DePuy Synthes orthopedics business for approximately $20 billion. A transaction could unlock value and sharpen J&J’s focus, although it would also remove a sizable source of revenue. TD Cowen J&J rating
• Positive Sentiment: Defensive and dividend appeal: Market commentary continues to identify J&J as a dependable dividend and defensive stock, attracting investors amid technology-sector volatility and concerns about AI safety. The company’s prior quarter also featured earnings and revenue above consensus, with full-year 2026 EPS guidance of $11.60-$11.75.
• Neutral Sentiment: Growth plan amid STELARA pressure: J&J is targeting double-digit growth while facing biosimilar competition for STELARA. Execution in oncology and newer products will be important to offset the loss of exclusivity.
• Negative Sentiment: Depression-drug trial failure: Contineum Therapeutics said JNJ-5120, or PIPE-307, failed to meet the primary endpoint in a mid-stage major depressive disorder study. The setback reduces the value of the program and highlights clinical-development risk. PIPE-307 trial failure
• Negative Sentiment: 340B program scrutiny: J&J reportedly requires providers to share claims data to receive certain 340B discounts, a policy that could invite criticism from hospitals and policymakers and create reimbursement or regulatory risk.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey’s 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey’s 7th Congressional District. He declared candidacy for the 2026 election.

Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.